Biocracked
Approach: the human outcome (a blood pressure reading in a real setting). Palette: D, bold color field.

Tight, slightly high-angle close-up of a bare upper arm wrapped in a matte charcoal blood pressure cuff, with the rubber tube curving across the frame. The arm rests on a table against a saturated tomato-red backdrop. A hand with a clean white sleeve cuff holds a stethoscope chest piece at the inner elbow. The face is out of frame. Soft, diffuse studio light from the upper left gives the skin natural warmth and subtle texture. The shadows are gentle, warm and reddish, with no blue cast. A small electric green (#00e676) digital gauge needle or LED glows on the cuff's inflation bulb, tucked in the lower right. The shallow depth of field blurs the background edges. The mood is clinical but bold, cautious and questioning, a measured result under scrutiny.
Supplements

NOVOS Core Lowered Blood Pressure 6 mmHg. Here's the Catch

Nova Chen · · 4 min read

A powder you stir into a drink every day, 12 ingredients, and a cardiology journal reporting better artery function after six months. That is the headline version of a new randomized trial of NOVOS Core. The full picture is more interesting, and more cautious, than the marketing-friendly version.

The study, published in European Heart Journal Open, is a double-blind randomized controlled trial from the University of Surrey and affiliated NHS teams. Here is what it found, what it did not find, and who should care.

The Headline Numbers

The trial (registered as NCT06145087) tested a multi-ingredient powder containing vitamins and minerals, amino acids, and plant-derived bioactives against a control. Participants were apparently healthy adults. All figures below are differences in change between the supplement and control groups after 6 months.

  • Endothelial function: flow-mediated dilation (FMD), the primary outcome, improved by 2.9 percentage points (95% CI 2.1 to 3.8).
  • Arterial stiffness: pulse wave velocity (PWV) fell by 1.18 m/s (95% CI -2.00 to -0.36).
  • Systolic blood pressure: peripheral SBP dropped by 6.1 mmHg (95% CI -10.9 to -1.3).
  • Estimated 10-year cardiovascular risk: SCORE2/SCORE2-OP fell by 0.45 percentage points (95% CI -0.86 to -0.03).
  • Lipids: unchanged.

FMD measures how well the inner lining of an artery relaxes in response to increased blood flow, and it is a widely used readout of endothelial health. PWV measures how fast the pulse wave travels along the arteries, and a higher speed means stiffer vessels. Both are surrogate markers, not heart attacks or strokes.

The Twist: It Wasn't Cholesterol

Many supplements get credit for "heart health" through lipid changes. This one did not move them. The authors attribute the small drop in estimated cardiovascular risk mainly to the lower systolic blood pressure, because SCORE2 calculations rely heavily on SBP, age, sex, smoking, and cholesterol. If lipids stayed flat, blood pressure is the main input that could have shifted the score.

The risk reduction is also modest in absolute terms. Participants started at a low baseline of 3.6 ± 2.9%, so a 0.45-point drop is a small change from an already low starting point. It is an estimate from a calculator, not an observed reduction in events.

How Solid Is the Evidence?

This is a randomized, double-blind human trial, which is a stronger design than animal work or observational data. Several limitations temper the result.

It is small. Sixty-one people were randomized (33 to the supplement, 28 to control), and only 43 completed both study visits (24 vs. 19). That is roughly 30% of participants lost, which can distort results if the people who dropped out differ from those who stayed.

The sponsor is involved. According to the conflict-of-interest statement, one author is an employee of NOVOS Labs, and senior author Christian Heiss has received research funding from NOVOS Labs. Industry involvement does not invalidate a trial, but it is a reason to want independent replication.

The population was healthy and low-risk. Findings in apparently healthy adults may not carry over to people with hypertension, diabetes, or established cardiovascular disease.

The outcomes are surrogates. Better FMD and PWV are encouraging signs, but the trial was not designed or powered to show fewer cardiovascular events.

The result is for the whole blend. With 12 ingredients combined, the study cannot say which component, if any single one, drove the effects.

What This Is Not

Despite the "longevity powder" label, this is not a biological-aging or lifespan result. The paper measures vascular function and blood pressure. It does not report epigenetic clocks, mortality, or lifespan. The authors describe the formulation as targeting pathways relevant to vascular ageing, and that framing is a hypothesis about mechanism, not proof of slowed aging.

The abstract also mentions an acute post-dose vascular assessment, but the headline results it reports are the 6-month effects.

Practical Takeaways

Dose and timing: The abstract describes daily intake over 6 months but does not give the specific serving size or time of day. Use the product's label directions and consult the full text (PMC13730552) for the protocol. Do not assume that more is better.

Who might find this relevant: Generally healthy adults who are already doing the basics (exercise, diet, sleep, not smoking) and are curious about adjunct strategies for vascular health. Even for them, the evidence is one small, sponsor-linked trial.

Who should be cautious or skip it:

  • People taking blood pressure medication, since an additive blood-pressure-lowering effect is possible. This is a general precaution, not something the paper tested.
  • Anyone on prescription drugs, pregnant or breastfeeding, or with a medical condition, who should check the ingredient list with a clinician first.
  • Anyone hoping a supplement can replace a statin, antihypertensive, or lifestyle change. This trial does not support that, and lipids did not change.
  • Anyone expecting proven anti-aging effects. This trial did not test that.

The Bottom Line

The trial gives a reasonably encouraging signal: a multi-ingredient powder was associated with better endothelial function, lower arterial stiffness, and lower systolic blood pressure over six months in healthy adults, with no change in cholesterol. But the sample was small, many participants dropped out, the manufacturer supplied support, and the outcomes are surrogate markers. The next step is larger, independent, longer trials that include higher-risk populations and ideally dissect which ingredients matter.

Sources: PubMed 42979377 | DOI: 10.1093/ehjopen/oeag157 | Trial registration NCT06145087

This article is for information only and is not medical advice.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

NC

Written by

Nova Chen

Nova Chen writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

**Approach:** Conceptual metaphor. **Palette:** Bold color field (teal).

A single flexible garden hose, shot from a low three-quarter angle, lies coiled against a saturated teal seamless backdrop. One half of the hose is pale and wrinkled, with a stiff, cracked rubber texture and a visible kink. The other half is supple, glossy and smoothly curved. A thin stream of water arcs from the open end, catching the light. Soft, large-source studio light comes from the upper left and casts gentle, neutral grey shadows with no blue cast. A small electric green brass fitting, with a clean metallic sheen, sits where the two halves meet. The shallow depth of field blurs the coils in the foreground. The mood is quietly doubtful but curious, as if the result is promising and still unproven. There is no text anywhere in the frame.
longevity

Magnesium Eased Stiff Arteries After 6 Months—Then Came a Null Trial

BY DR. SYNAPSE ·

For 12 weeks, magnesium did nothing measurable to arterial stiffness. At week 24, a 52-person randomized trial found pulse wave velocity improved by 1.0 m/s versus placebo, with no change in blood pressure. It's an eye-catching result for anyone interested in vascular aging. But a larger 2022 follow-up from the same group, testing 164 adults and three magnesium forms, found no significant effect. Here's what the original study showed, where it falls short, and what to make of the conflicting evidence.

Approach 3, the human outcome, in palette D, a bold color field.

Close-up of an older adult's bare upper arm, seen from a slightly high three-quarter angle, with a blood pressure cuff wrapped snugly above the elbow. The cuff is matte graphite grey with a coiled rubber tube trailing out of frame. The arm shows real skin texture, freckles and fine creases, and the face is out of frame. The backdrop is a saturated, flat tomato-red wall. A small electric green LED glows on the cuff's digital monitor at the edge of the frame, with its display blurred and unreadable. Soft, even studio light comes from the left, with gentle shadows and no blue cast. Shallow depth of field keeps the cuff edge and skin pores sharp. The mood is calm, clinical and quietly hopeful.
supplements

NMN and Blood Pressure: 10 Trials Pooled, Over-60s Dropped Most

BY NOVA CHEN ·

A new meta-analysis in Nutrients pooled 10 randomized trials of NMN, the popular NAD+ precursor, to see whether it affects blood pressure. Across 349 participants, NMN modestly lowered diastolic pressure by about 2.15 mmHg, while the overall systolic change was not significant. In adults 60 and older, systolic pressure dropped by roughly 3.94 mmHg. But the sample is small, the analysis used a common-effects model, and the authors call the evidence preliminary. Here is what the numbers mean, what they don't, and why NMN is no substitute for blood pressure medication.

Approach 3, the human outcome, in palette B, warm.

Low three-quarter rear angle, shot with a 50mm lens at shallow depth of field. A middle-aged person's forearm and hand grip a loaded barbell mid-deadlift, the tendons and the muscle of the forearm clearly defined, with chalk dust hanging in the air. Their face is out of frame. The setting is a plain home garage gym with a rubber floor and a rack softly blurred in the background. Low golden-hour sunlight comes through an open roll-up door and rakes across the skin and the knurled steel, casting long warm shadows. Amber, copper and honey tones dominate, with matte black plates for contrast. A tiny electric green silicone wristband or a small green pen injector resting on a nearby shelf adds a subtle accent. The mood is determined, quiet and hopeful.
metabolism

On Tirzepatide? Lifting Weights Saved 1.1 kg of Lean Mass

BY REX MERIDIAN ·

Tirzepatide can melt away over 22 kg in 40 weeks, but it also takes lean tissue and strength with it. A new randomized trial of 120 adults tested whether lifting weights three times a week could change that. Fat loss stayed the same, but lifters lost about 1.1 kg less lean soft tissue. Strength fell in the drug-only group and rose in every test among lifters. Here are the numbers and what they mean for anyone on Mounjaro or Zepbound.

Approach: human outcome. Palette: natural.

Close, low-angle shot of an older adult's bare lower leg and bare feet resting on crisp white hospital bed linen, with a soft, out-of-focus window in the background. The camera sits at mattress level and looks along the calf toward the ankle. Face is not visible. A small ultrasound probe coated in clear gel presses against the back of the knee. The operator's gloved hand enters from the frame edge. Soft overcast daylight from the window gives skin tones a warm, realistic look. Around the bed, a sprig of fresh rosemary and a few purple-green ashwagandha leaves sit on a wooden bedside tray. The leaves provide plant-green accents, along with one small electric green sensor light on a monitor. Palette: natural greens, wood browns and warm skin. Mood: quiet, careful and hopeful.
supplements

PB125: The Herbal Nrf2 Blend That Kept Arteries Working in Bed Rest

BY NOVA CHEN ·

A botanical Nrf2 activator called PB125, made from rosemary, ashwagandha and luteolin, has now been tested in a small, double-blind human trial. In 24 older adults, two weeks at 200 mg/day raised brachial FMD from 2.8% to 3.8% and popliteal FMD from 1.5% to 2.3%. During five days of bed rest, the blend preserved artery function and antioxidant levels compared with placebo. Younger adults saw no baseline FMD gain, though PB125 protected popliteal FMD during limb immobilization. With only 44 participants and surrogate endpoints, it's a promising signal rather than proof of clinical benefit.

This page is available in